Immunogenicity of a receptor-binding domain of SARS coronavirus spike protein in mice: Implications for a subunit vaccine

Vaccine

Volumn 25, Issue 1, 2007, Pages 136-143

  Zakhartchouk, Alexander N ^a   Sharon, Chetna ^b,e   Satkunarajah, Malathy ^b,e   Auperin, Thierry ^b,e   Viswanathan, Sathiyanarayanan ^a   Mutwiri, George ^a   Petric, Martin ^c   See, Raymond H ^c   Brunham, Robert C ^c   Finlay, B Brett ^d   Cameron, Cheryl ^f   Kelvin, David J ^f   Cochrane, Alan ^b   Rini, James M ^b,e   Babiuk, Lorne A ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Receptor binding domain; SARS coronavirus; Spike protein; Subunit vaccine

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; GAMMA INTERFERON; IMMUNOGLOBULIN G2A; SEVERE ACUTE RESPIRATORY SYNDROME VACCINE; VITRONECTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN BINDING; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; IMMUNIZATION; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PURIFICATION; PROTEIN SYNTHESIS; RECEPTOR BINDING; SARS CORONAVIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; SPLEEN;

ALUM COMPOUNDS; ANIMALS; ANTIBODIES, VIRAL; CELL LINE; FEMALE; HUMANS; INTERFERON TYPE II; MEMBRANE GLYCOPROTEINS; MICE; OLIGODEOXYRIBONUCLEOTIDES; RECEPTORS, VIRUS; SARS VIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; VIRAL ENVELOPE PROTEINS; VIRAL VACCINES;

EID: 33845194637     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.06.084     Document Type: Article

References (38)

1. Skowronski D.M., Astell C., Brunham R.C., Low D.E., Petric M., Roper R.L., et al. Severe acute respiratory syndrome (SARS): a year in review. Annu Rev Med 56 (2005) 357-381
2. Marra M.A., Jones S.J., Astell C.R., Holt R.A., Brooks-Wilson A., Butterfield Y.S., et al. The genome sequence of the SARS-associated coronavirus. Science 300 (2003) 1399-1404
3. Rota P.A., Oberste M.S., Monroe S.S., Nix W.A., Campagnoli R., Icenogle J.P., et al. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 300 (2003) 1394-1399
4. Weiss S.R., and Navas-Martin S. Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus. Microbiol Mol Biol Rev 69 4 (2005) 635-664
5. Gallagher T.M., and Buchmeier M.J. Coronavirus spike proteins in viral entry and pathogenesis. Virology 279 2 (2001) 371-374
6. Godet M., Grosclaude J., Delmas B., and Laude H. Major receptor-binding and neutralization determinants are located within the same domain of the transmissible gastroenteritis virus (coronavirus) spike protein. J Virol 68 12 (1994) 8008-8016
7. Li W., Moore M.J., Vasilieva N., Sui J., Wong S.K., Berne M.A., et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 426 6965 (2003) 450-454
8. Babcock G.J., Esshaki D.J., Thomas Jr. W.D., and Ambrosino D.M. Amino acids 270 to 510 of the severe acute respiratory syndrome coronavirus spike protein are required for interaction with receptor. J Virol 78 9 (2004) 4552-4560
9. Wong S.K., Li W., Moore M.J., Choe H., and Farzan M. A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2. J Biol Chem 279 5 (2004) 3197-3201
10. ter Meulen J., Bakker A.B., van den Brink E.N., Weverling G.J., Martina B.E., Haagmans B.L., et al. Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets. Lancet 363 9427 (2004) 2139-2141
11. Greenough T.C., Babcock G.J., Roberts A., Hernandez H.J., Thomas Jr. W.D., Coccia J.A., et al. Development and characterization of a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice. J Infect Dis 91 4 (2005) 507-514
12. Bisht H., Roberts A., Vogel L., Bukreyev A., Collins P.L., Murphy B.R., et al. Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. Proc Natl Acad Sci USA 101 17 (2004) 6641-6646
13. Bukreyev A., Lamirande E.W., Buchholz U.J., Vogel L.N., Elkins W.R., St Claire M., et al. Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS. Lancet 363 9427 (2004) 2122-2127
14. Yang Z.Y., Kong W.P., Huang Y., Roberts A., Murphy B.R., Subbarao K., et al. A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature 428 6982 (2004) 561-564
15. Taylor D.R. Obstacles and advances in SARS vaccine development. Vaccine 24 7 (2006) 863-871
16. Stark C.J., and Atreya C.D. Molecular advances in the cell biology of SARS-CoV and current disease prevention strategies. Virol J 2 (2005) 35
17. See R.H., Zakhartchouk A.N., Petric M., Lawrence D.J., Mok C.P.Y., Hogan R.J., et al. Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus. J Gen Virol 87 (2006) 641-650
18. Sanchez-Lopez R., Nicholson R., Gesnel M.C., Matrisian L.M., and Breathnach R. Structure-function relationships in the collagenase family member transin. J Biol Chem 263 24 (1988) 11892-11899
19. Zakhartchouk A.N., Liu Q., Petric M., and Babiuk L.A. Augmentation of immune responses to SARS coronavirus by a combination of DNA and whole killed virus vaccines. Vaccine 23 35 (2005) 4385-4391
20. Bisht H., Roberts A., Vogel L., Subbarao K., and Moss B. Neutralizing antibody and protective immunity to SARS coronavirus infection of mice induced by a soluble recombinant polypeptide containing an N-terminal segment of the spike glycoprotein. Virology 334 2 (2005) 160-165
21. Chakraborti S., Prabakaran P., Xiao X., and Dimitrov D.S. The SARS coronavirus S glycoprotein receptor binding domain: fine mapping and functional characterization. Virol J 2 (2005) 73
22. Comoy E.E., Capron A., and Thyphronitis G. In vivo induction of type 1 and 2 immune responses against protein antigens. Int Immunol 9 4 (1997) 523-531
23. HogenEsch H. Mechanisms of stimulation of the immune response by aluminum adjuvants. Vaccine 20 Suppl. 3 (2002) S34-S39
24. Harandi A.M., Eriksson K., and Holmgren J. A protective role of locally administered immunostimulatory CpG oligodeoxynucleotide in a mouse model of genital herpes infection. J Virol 77 2 (2003) 953-962
25. Rao M., Matyas G.R., Vancott T.C., Birx D.L., and Alving C.R. Immunostimulatory CpG motifs induce CTL responses to HIV type I oligomeric gp140 envelope protein. Immunol Cell Biol 82 5 (2004) 523-530
26. Rankin R., Pontarollo R., Gomis S., Karvonen B., Willson P., Loehr B.I., et al. CpG-containing oligodeoxynucleotides augment and switch the immune responses of cattle to bovine herpesvirus-1 glycoprotein D. Vaccine 20 23-24 (2002) 3014-3022
27. Weeratna R., Comanita L., and Davis H.L. CPG ODN allows lower dose of antigen against hepatitis B surface antigen in BALB/c mice. Immunol Cell Biol 81 1 (2003) 59-62
28. Zhang J., Liu Y., Hu L., Gao Q., Zhang Z., Zhang X., et al. Preparation and characterization of SARS in-house reference antiserum. Vaccine 23 48-49 (2005) 5666-5669
29. Sui J., Li W., Murakami A., Tamin A., Matthews L.J., Wong S.K., et al. Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association. Proc Natl Acad Sci USA 101 8 (2004) 2536-2541
30. van den Brink E.N., Ter Meulen J., Cox F., Jongeneelen M.A., Thijsse A., Throsby M., et al. Molecular and biological characterization of human monoclonal antibodies binding to the spike and nucleocapsid proteins of severe acute respiratory syndrome coronavirus. J Virol 79 3 (2005) 1635-1644
31. He Y., Lu H., Siddiqui P., Zhou Y., and Jiang S. Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies. J Immunol 174 8 (2005) 4908-4915
32. He Y., Zhou Y., Liu S., Kou Z., Li W., Farzan M., et al. Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine. Biochem Biophys Res Commun 324 2 (2004) 773-781
33. Hogan R.J., Gao G., Rowe T., Bell P., Flieder D., Paragas J., et al. Resolution of primary severe acute respiratory syndrome-associated coronavirus infection requires stat1. J Virol 78 (2004) 11416-11421
34. Zhou Z., Post P., Chubet R., Holtz K., McPherson C., Petric M., et al. A recombinant baculovirus-expressed S glycoprotein vaccine elicits high titers of SARS-associated coronavirus (SARS-CoV) neutralizing antibodies in mice. Vaccine 24 (2006) 3624-3631
35. Li F., Li W., Farzan M., and Harrison S.C. Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science 309 5742 (2005) 1864-1868
36. Vennema H., de Groot R.J., Harbour D.A., Dalderup M., Gruffydd-Jones T., Horzinek M.C., et al. Early death after feline infectious peritonitis virus challenge due to recombinant vaccinia virus immunization. J Virol 64 3 (1990) 1407-1409
37. Yang Z.Y., Werner H.C., Kong W.P., Leung K., Traggiai E., Lanzavecchia A., et al. Evasion of antibody neutralization in emerging severe acute respiratory syndrome coronaviruses. Proc Natl Acad Sci USA 102 3 (2005) 797-801
38. Weingartl H., Czub M., Czub S., Neufeld J., Marszal P., Gren J., et al. Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets. J Virol 78 (2004) 12672-12676